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ABSTRACT 1 
Cannabinoids have been demonstrated to exert neuroprotective effects on 2 
different types of neuronal insults. Here we have addressed the therapeutic 3 
potential of the synthetic cannabinoid HU210 on photoreceptor degeneration, 4 
synaptic connectivity and functional activity of the retina in the transgenic P23H 5 
rat, an animal model for autosomal dominant retinitis pigmentosa (RP). In P23H 6 
rats administered with HU210 (100 µg/kg, i.p.) from P24 to P90, ERG 7 
recordings showed an amelioration of vision loss, as compared to vehicle-8 
administered animals. Under scotopic conditions, the maximum a-wave 9 
amplitudes recorded at P60 and P90 were higher in HU210-treated animals, as 10 
compared to the values obtained in untreated animals. The scotopic b-waves 11 
were significantly higher in treated animals than in untreated rats at P30, P60 12 
and P90. This attenuation of visual deterioration correlated with a delay in 13 
photoreceptor degeneration and the preservation of retinal cytoarchitecture. 14 
HU210-treated animals had 40% more photoreceptors than untreated animals. 15 
Presynaptic and postsynaptic elements, as well as the synaptic contacts 16 
between photoreceptors and bipolar or horizontal cells, were also preserved in 17 
HU210-treated P23H rats. These results indicate that HU210 preserves cone 18 
and rod structure and function, together with their contacts with postsynaptic 19 
neurons, in P23H rats. These data suggest that cannabinoids are potentially 20 
useful to delay retinal degeneration in RP patients. 21 
 22 
Key words: Neurodegeneration, retinitis pigmentosa, P23H, apoptosis, 23 
electroretinography, immunohistochemistry, confocal microscopy 24 
 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
Abbreviations: CB1 and CB2, Cannabinoid receptor type 1 and 2; ERG, 1 
electroretinogram; GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner 2 
plexiform layer; IS, inner segment; ONF, optic nerve fibers; ONL, outer nuclear 3 
layer; OPL, outer plexiform layer; OS, outer segment; PB, phosphate buffer; 4 
PKC-α, α isoform of protein kinase C; RHO, rhodopsin-encoding gene; RP, 5 
retinitis pigmentosa; ROS, reactive oxygen species; SYP, synaptophysin; THC, 6 
∆9-tetrahydrocannabinol 7 
8 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4
1. Introduction 1 
Retinitis pigmentosa (RP) is a family of inherited neurodegenerative retinal 2 
disorders with an incidence in humans of approximately 1/4000 (Hartong et al., 3 
2006). The disease is characterized by a progressive peripheral vision loss and 4 
night vision difficulties, subsequently leading to central vision impairment. More 5 
than 100 different mutations in the rhodopsin-encoding gene (RHO) are 6 
associated with RP, together accounting for 30-40% of autosomal dominant 7 
cases. The P23H mutation in this gene is the most prevalent cause of RP (Dryja 8 
et al., 1990), which alone accounts for approximately 12% of autosomal 9 
dominant RP cases in the United States (Dryja et al., 2000). The majority of RP-10 
causing mutations in the RHO gene, including P23H, cause misfolding and 11 
retention of rhodopsin in the endoplasmic reticulum of transfected cultured cells 12 
(Kaushal and Khorana, 1994). These studies also suggest that the mechanism 13 
of RP involves a cellular stress response (Illing et al., 2002), the final common 14 
pathway being programmed photoreceptor cell death, or apoptosis (Reme et 15 
al., 1998). P23H transgenic albino rats suffer from a progressive retinal 16 
degeneration, which is consistent with the clinical findings in P23H patients 17 
(Berson et al., 1991; Cuenca et al., 2004; Machida et al., 2000; Pinilla et al., 18 
2005). The loss of photoreceptors is accompanied by degenerative changes in 19 
the inner retina (Cuenca et al., 2004), and a substantial degeneration of retinal 20 
ganglion cells (Garcia-Ayuso et al., 2010; Kolomiets et al., 2010). 21 
Several strategies are being investigated to slow or cure this group of 22 
diseases. Gene therapy, encapsulated cells releasing neurotrophic factors and 23 
stem cell transplantation are promising future approaches to RP treatment 24 
(Fernandez-Sanchez et al., 2012b; Musarella and Macdonald, 2011; Stieger, 25 
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2010). Molecules that promote survival, such as brain-derived neurotrophic 1 
factor, ciliary neurotrophic factor, fibroblast growth factor, glial-derived 2 
neurotrophic factor, pigment epithelium-derived factor, and proinsulin 3 
(Fernandez-Sanchez et al., 2012b), are moderately successful in preventing the 4 
progression of the disease when used in animal models (Cayouette et al., 1998; 5 
Cayouette et al., 1999; Chong et al., 1999; Green et al., 2001; McGee Sanftner 6 
et al., 2001; Okoye et al., 2003). Antioxidants have also been shown to be 7 
effective in preventing retinal degeneration in animal models of RP, probably by 8 
reducing oxidative damage (Ahuja et al., 2005; Berson et al., 1993; Fernandez-9 
Sanchez et al., 2012a; Komeima et al., 2006; Lax et al., 2011). Finally, 10 
attenuation of apoptosis represents a good therapeutic target in RP, especially 11 
considering the vast heterogeneity of the disease (Doonan and Cotter, 2004; 12 
Fernandez-Sanchez et al., 2011; Liang et al., 2001). In the meantime, it would 13 
be thus interesting to address other potential treatments making it possible, if 14 
not to cure, at least to delay RP progression in the short term. 15 
Cannabinoids have been reported to attenuate brain damage caused by 16 
different types of insults (Fernandez-Ruiz et al., 2010; Pertwee, 2012; van der 17 
Stelt and Di Marzo, 2005; Zogopoulos et al., 2013). Previous studies have 18 
shown neuroprotective effects of cannabinoids in the retina (Yazulla, 2008). 19 
Thus, it is known that CB1 agonists protect ganglion cells from glutamate-20 
mediated excitotoxicity (El-Remessy et al., 2003; Opere et al., 2006) and 21 
ischemia caused by increased intraocular pressure (Crandall et al., 2007; Nucci 22 
et al., 2007; Pinar-Sueiro et al., 2013). HU210 is a synthetic analogue of ∆9-23 
tetrahydrocannabinol (THC), the primary psychoactive constituent in marihuana 24 
(Mechoulam et al., 1988). The aim of this study was to evaluate, by means of 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6
functional (ERG) and morphological (histological labeling) techniques, the 1 
effectiveness of HU210 as a neuroprotective agent on homozygous P23H line 3 2 
rats, characterized by a relatively slow retinal degeneration. Since one of the 3 
first signs of degeneration in these animals was found in the outer plexiform 4 
layer (OPL) (Cuenca et al., 2004; Pinilla et al., 2005), we also evaluated its 5 
capacity to prevent the loss of synaptic contacts at this retinal location. A 6 
positive assessment of the action of cannabinoids in this animal model could 7 
lead to its possible preventive use in patients affected with RP. 8 
9 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7
2. Materials and methods 1 
2.1. Animals and HU210 administration 2 
Homozygous P23H line 3 rats, obtained from M. LaVail (UCSF School of 3 
Medicine; http://www.ucsfeye.net/mlavailRDratmodels.shtml), were used as a 4 
model of RP. All animals were bred in a colony at the University of Alicante and 5 
maintained under controlled humidity (60%), temperature (23 ± 1ºC) and 6 
photoperiod (LD 12:12) conditions. Light was provided by two fluorescent 7 
lamps, with an intensity of 350-400 lux at cage level. Dry food and water were 8 
made available ad libitum. All animals were handled in accordance with current 9 
regulations for the use of laboratory animals (NIH, ARVO and European 10 
Directive 2010/63/UE) in order to minimize animal suffering and limit the 11 
numbers used for the experiments. 12 
HU210, purchased from Tocris (Tocris Bioscience, Bristol, UK), was 13 
resuspended to stock concentration (5 mg/ml) in ethanol and refrigerated at 14 
−20°C until administration. After being diluted in physiological saline (0.9% 15 
NaCl), HU210 was administered at 100 µg/kg (i.p.) three times a week from P24 16 
to P90, when P23H line 3 rats can be considered to have undergone extensive 17 
retinal degeneration (http://www.ucsfeye.net/mlavailRDratmodels.shtml) 18 
(Fernandez-Sanchez et al., 2012a; Fernandez-Sanchez et al., 2012b; 19 
Fernandez-Sanchez et al., 2011). Untreated animals received the same volume 20 
of saline at the same time points. In order to adjust the amount of HU210 and 21 
vehicle administered, the animal body weight was measured before each drug 22 
injection. 23 
 24 
2.2. ERG recordings  25 
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Scotopic ERGs were performed at P30, P60 and P90, at least 24 h after the 1 
last administration of HU210. Following overnight dark adaptation, animals were 2 
prepared for bilateral ERG recording under dim red light. Animals were 3 
anesthetized by i.p. injection of a ketamine (100 mg/kg) plus xylazine (4 mg/kg) 4 
solution, and maintained on a heating pad at 38 °C.  Pupils were dilated by 5 
topical application of 1% tropicamide (Alcon Cusí, Barcelona, Spain). A drop of 6 
Viscotears 0.2% polyacrylic acid carbomer (Novartis, Barcelona, Spain) was 7 
instilled on the cornea to prevent dehydration and allow electrical contact with 8 
the recording electrodes. These were DTL fiber electrodes with an X-Static 9 
silver-coated nylon conductive strand, from Sauquoit Industries (Scranton, PA). 10 
A 25-gauge platinum needle inserted under the scalp between the eyes served 11 
as the reference electrode. A gold electrode was placed in the mouth and 12 
served as ground. Anesthetized animals were placed in a Faraday cage and all 13 
experiments were performed in absolute darkness. Scotopic flash-induced ERG 14 
responses were recorded from both eyes in response to light stimuli produced 15 
by a Ganzfeld stimulator. Light stimuli were presented for 10 ms at 11 different 16 
increasing luminances (ranging from -5.2 to 0 log cd·s/m-2). Three to ten 17 
consecutive recordings were averaged for each light presentation. The interval 18 
between light flashes was 10 s for dim flashes (-5.2 to -1.4 log cd·s/m-2) and up 19 
to 20 s for the higher luminances (-0.8 to 0 log cd·s/m-2). The ERG signals were 20 
amplified and band-pass filtered (1-1000 Hz, without notch filtering) using a 21 
DAM50 data acquisition board (World Precision Instruments, Aston, UK). 22 
Stimulus presentation and data acquisition (4 kHz) were performed using a 23 
PowerLab system (AD Instruments, Oxfordshire, UK). Recordings were saved 24 
on a computer and analyzed off-line. The amplitude of the a-wave was 25 
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measured from the baseline at 10 ms after the onset of the light stimulus, a 1 
point before the intrusion of the b-wave. The amplitude of the b-wave was 2 
measured from the trough of the a-wave to the peak of the b-wave. Thresholds 3 
were defined as the minimal luminance required to reach the criterion amplitude 4 
of 10 µV, calculated via curve-fitting (three-parameter sigmoid function) of the 5 
luminance-response curve obtained for each series of stimuli. Latency (time-to-6 
peak) was measured from stimulus onset to the a-wave trough and b-wave 7 
peak. 8 
 9 
2.3. Retinal sections 10 
Animals were sacrificed in the morning by administration of a lethal dose of 11 
pentobarbital. After marking the dorsal margin of the limbus with a suture, eyes 12 
were enucleated and fixed in 4% (w/v) paraformaldehyde during 1 h at room 13 
temperature. After being washed in 0.1 M phosphate buffer pH 7.4 (PB), eyes 14 
were cryoprotected sequentially in 15, 20 and 30% sucrose. The cornea, lens 15 
and vitreous body were removed, and the retinas were processed for vertical 16 
sections. For this purpose, they were embedded in OCT and frozen in liquid N2. 17 
Sixteen µm-thick sections were then obtained at -25 ºC, mounted on Superfrost 18 
Plus slides (Menzel GmbH & Co KG, Braunschweig, Germany), and air-dried. 19 
Before further use, slides were washed 3 times in PB, and then treated with 20 
blocking solution (10% normal donkey serum in PB plus 0.5% Triton X-100) for 21 
1 h. 22 
 23 
2.4. Retinal immunohistochemistry 24 
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For objective comparison, retinas from vehicle- and HU210-treated rats 1 
were fully processed in parallel. All primary antibodies used in this work 2 
(summarized in Table 1) have been used in several previous studies and have 3 
been well characterized by us and other authors regarding specific cell type 4 
molecular markers. Sections were subjected to single or double immunostaining 5 
overnight at room temperature, with combinations of antibodies for different 6 
molecular markers at the dilutions indicated in Table 1, in PB containing 0.5% 7 
Triton X-100. Subsequently, Alexa Fluor 488 (green)-conjugated anti-rabbit IgG 8 
and/or Alexa Fluor 555 (red)-conjugated anti-mouse IgG donkey secondary 9 
antibodies from Molecular Probes (Eugene, OR) were applied at a 1:100 10 
dilution for 1 h. The sections were finally washed in PB, mounted in Citifluor 11 
(Citifluor Ltd; London, UK) and coverslipped for viewing under laser-scanning 12 
confocal microscopy on a Leica TCS SP2 system (Wetzlar, Germany). 13 
Immunohistochemical controls were performed by omission of either the 14 
primary or secondary antibodies. Final images from control and experimental 15 
subjects were processed in parallel using the Adobe Photoshop 10 software 16 
(Adobe Systems Inc., San Jose, CA). Unless otherwise indicated, all the images 17 
analyzed were collected from the central area of the retina, close to the optic 18 
nerve. 19 
 20 
2.5. Morphometric analysis 21 
Five animals per group were examined. For measurements of the outer 22 
nuclear layer (ONL) thickness, a nuclear stain (Hoechst; Sigma, Milwaukee, WI) 23 
was added at 1 µg/ml to at least 4 sections from each animal containing the 24 
optic nerve and both temporal and nasal ora serratas. Counting of 25 
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photoreceptor rows was performed each 0.5 mm from the optic nerve toward 1 
each ora serrata. The number of photoreceptor rows was the average of three 2 
measurements counting rows of nuclei of photoreceptor cells. For quantification 3 
of the relative number of synaptic ribbons in the OPL, we counted the number 4 
of Bassoon-immunoreactive puncta in 2 retinal sections from each animal 5 
containing the optic nerve and both temporal and nasal ora serratas. 6 
Measurements were performed close to the optic nerve, and at 2 and 4 mm 7 
from the optic nerve toward each ora serrata. Total length of cones was 8 
measured using γ-transducin stained retinal sections. Measurements were 9 
performed in the central retina, temporal and nasal, close to the optic nerve, in 10 
at least 5 cones from each animal. For evaluation of the ON-rod bipolar cells 11 
integrity, we measured the intensity of PKC-α immunoreactivity using the 12 
ImageJ software. Fluorescence intensity values were obtained in each animal 13 
from 2 pictures of central retinal sections, temporal and nasal, close to the optic 14 
nerve. Preservation of photoreceptor presynaptic terminals was evaluated by 15 
measuring the relative area of synaptophysin immunostaining in the OPL (µm2 16 
of positive staining per mm of retinal section). Measurements were performed in 17 
each animal from 2 pictures of central retinal sections, temporal and nasal, 18 
close to the optic nerve. All quantifications were done in a blinded fashion by 19 
multiple experienced observers.  20 
 21 
2.6. Statistical analysis 22 
Statistical analyses were performed using SPSS 18.0 software (IBM 23 
Armonk, NY). A repeated measures factorial analysis of variance (MANOVA) 24 
was performed to evaluate the effects of the treatment (vehicle vs. HU210) on 25 
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ERG responses throughout the experimental stages (P30, P60 and P90), as 1 
well as the interactions among them. When a 0.05 level of significance was 2 
found, post hoc pairwise comparisons using Bonferroni’s test were made. 3 
Normal distributions and homogeneity of variance were found for all analyzed 4 
categories. A paired Student’s t-test was used to evaluate morphological 5 
parameters. A regression analysis was performed to establish the relationship 6 
between retinal function (by means of the maximum amplitudes of scotopic a- 7 
and b-waves) and ONL thickness (taken as an indicator of the number of 8 
photoreceptors in the retina). p values less than 0.05 were considered 9 
statistically significant. Data were plotted as the mean ± standard error of the 10 
mean (SEM). 11 
 12 
13 
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3. Results 1 
3.1. HU210 preserves retinal responsiveness 2 
In order to evaluate the effect of HU210 on the functional activity of the 3 
retina in P23H rats, scotopic flash-induced ERG responses were recorded in 4 
vehicle- and HU210-treated animals (n = 6 and n = 5, respectively). As shown in 5 
Fig. 1, ERG responsiveness was less deteriorated in P23H rats treated with 6 
HU210 (P24 to P90), as compared to vehicle-administered P23H rats. The 7 
maximum amplitudes recorded for a-waves at P60 and P90 under scotopic 8 
conditions were higher in HU210-treated animals than those recorded in 9 
untreated animals (ANOVA, Bonferroni’s test, p < 0.05 in both cases; Fig. 1A, 10 
1C, 1D). Mean b-wave responses were higher in HU210-treated P23H rats, as 11 
compared to vehicle-administered animals, at P30, P60 and P90 (ANOVA, 12 
Bonferroni’s test, p < 0.001 in all cases; Fig. 1A-D). The highest differences in 13 
a- and b-wave amplitudes between HU210 and vehicle-administered P23H rats 14 
were observed at P90, when the maximum scotopic a-wave (a-max) and b-15 
wave (b-max) amplitude recorded in treated animals resulted, respectively, 71% 16 
and 70% higher than that recorded in untreated animals. Thresholds in HU210-17 
treated animals, compared with untreated rats, were lower for scotopic b-waves 18 
at P90 (ANOVA, Bonferroni’s test, p < 0.05; -5.4 ± 0.2 log cd·s/m2 vs. -4.9 ± 0.2 19 
log cd·s/m2; Fig. 1D). The mean latency of the scotopic a- and b-waves was 20 
lower in HU210-treated P23H rats, as compared to vehicle-administered 21 
animals, at P60 (ANOVA, Bonferroni’s test, p < 0.01 in both cases; 26.0 ± 0.6 22 
ms vs. 29.9 ± 1.3 ms for a-max, 61.3 ± 1.5 ms vs. 66.4 ± 1.2 ms for b-max) and 23 
P90 (ANOVA, Bonferroni’s test, p < 0.01 in both cases; 23.0 ± 1.0 ms vs. 29.7 ± 24 
2.1 ms for a-max, 64.2 ± 3.0 ms vs. 71.9 ± 3.2 ms for b-max). 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14 
 1 
3.2. HU210 slows photoreceptor degeneration 2 
To assess the protective action of HU210 on photoreceptors, we analyzed 3 
the thickness of the ONL in each retina at P90. Figure 2 shows vertical sections 4 
and magnifications of retinas from a P23H rat treated with HU210 (Fig. 2B) or 5 
vehicle (Fig. 2A). Few rows of photoreceptor cell bodies could be observed in 6 
the ONL of the vehicle-administered rats, as compared with the rows present in 7 
the retina of the HU210-treated P23H animals. Because retinal degeneration in 8 
untreated P23H rats was not homogeneous throughout the retina, we measured 9 
the effects of HU210 in different retinal areas, from temporal to nasal. We found 10 
that ONL thickness was greater in HU210-treated rats (n = 5) than in untreated 11 
animals (n = 5) in all examined areas (Student’s t-test, p < 0.01; Fig. 3A). On 12 
average, the mean number of photoreceptor rows in HU210-treated P23H rats 13 
was 40% higher than observed in vehicle-administered P23H rats (2.6 ± 0.2 µm 14 
vs. 1.8 ± 0.2 µm; Fig. 3A). The mean number of rows of photoreceptor cell 15 
bodies found in HU210- and vehicle-administered rat retinas positively 16 
correlated with the maximum scotopic ERG b-wave amplitude recorded for each 17 
animal at P90 (p < 0.01). 18 
We next explored whether the conservation of photoreceptor number 19 
was accompanied by a preservation of synaptic connectivity in the OPL. To this 20 
end, we used antibodies against bassoon, a protein constituent of synaptic 21 
ribbons present in both rod spherules and cone pedicles in the OPL (Cuenca et 22 
al., 2004). Few bassoon-immunopositive spots were found at the OPL level in 23 
P23H untreated rats, as compared with the number of immunoreactive puncta 24 
present in the retina of HU210-treated animals (Fig. 7E, 7F; arrows). Since 25 
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retinal degeneration was not homogeneous throughout the retina in P23H rats, 1 
we measured the relative number of positively stained ribbons in different retinal 2 
areas, from temporal to nasal (Figure 3B). We found that the mean number of 3 
Bassoon-immunoreactive puncta in HU210-treated P23H rats was 25% higher 4 
(Student’s t-test, p < 0.01) than observed in untreated animals (32.5 ± 2.6 vs. 5 
26.0 ± 2.3 stained synaptic ribbons/100µm, n = 5 in both cases; Fig. 3B), 6 
indicating that the presynaptic contact elements between photoreceptors and 7 
bipolar or horizontal cells were at least partially preserved. 8 
 9 
3.3. HU210 preserves photoreceptor morphology 10 
In order to evaluate whether HU210-treatment was able to preserve the 11 
morphology of photoreceptors, we examined the staining pattern of antibodies 12 
against recoverin, a marker for rods, cones and two bipolar cell subtypes 13 
(Cuenca et al., 2004), rhodopsin, which stains rod outer segments (Pinilla et al., 14 
2007), and γ-transducin, a marker for cones (Cuenca et al., 2004). Longer rod 15 
inner and outer segments were observed for HU210-treated P23H rats (Fig. 4C) 16 
than for vehicle-administered animals (Fig. 4B), where rod degeneration was 17 
evident to a greater degree. Drastic changes with age were also observed in 18 
the cone photoreceptors of vehicle-administered P23H rats. At P90, their outer 19 
segments were both short and swollen and very small in size (Fig. 4E, 4H). The 20 
axons were also absent and pedicles emerged directly from the cone cell 21 
bodies. In contrast, the typical cone shape can be observed in HU210-treated 22 
P23H rats (Fig. 4F, 4I), where outer and inner segments were clearly identified 23 
(Fig. 4I; arrows), and axon and pedicle morphology were preserved (Fig. 4I; 24 
arrowheads). Mean length of cones in both treated and untreated P23H rats 25 
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was smaller than that observed in SD rats (Student’s t-test, p < 0.01 in both 1 
cases; Fig. 3C). However, HU210-treated P23H rat retinas showed cone 2 
photoreceptors 50% longer than in untreated P23H rat retinas (Student’s t-test, 3 
p < 0.05; Fig. 3C). 4 
 5 
3.4. HU210 preserves bipolar cells and their synaptic contacts in both plexiform 6 
layers 7 
Two bipolar cell subtypes are labeled with antibodies against recoverin 8 
(Cuenca et al., 2004): type 8 ON-cone bipolar cells, with weakly 9 
immunoreactive cell bodies located near the OPL and a diffuse plexus of axons 10 
terminating in strata S4-S5 of the inner plexiform layer (IPL) (Fig. 4A-4C; 11 
arrows), and type 2 OFF-cone bipolar cells, with strongly immunoreactive cell 12 
bodies located in the middle of the inner nuclear layer (INL) and a dense 13 
continuous plexus in strata S1 and S2 of the IPL (Fig. 4A-4C; arrowheads) 14 
(Cuenca et al., 2004). On the other hand, γ-transducin antibodies immunostain 15 
some types of cone bipolar cells in the rat retina, whose axon terminals are 16 
located in all strata of the IPL (Fig. 4D-4I) (Martinez-Navarrete et al., 2011). In 17 
HU210-treated rats, bipolar cells immunostained with antibodies against both 18 
recoverin and γ-transducin showed (Fig. 4C, 4F) more immunoreactivity and a 19 
more complex plexus in the IPL, than that observed in untreated animals (Fig. 20 
4B, 4E). 21 
ON-rod bipolar cells are labeled with antibodies against the α isoform of 22 
protein kinase C (PKC-α) (Cuenca et al., 2004). In the rat retina, dendritic 23 
terminals of ON-rod bipolar cells establish connections with rod spherules 24 
through a large dendritic arbor in the OPL, and their axons ran into the IPL, 25 
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each one ending in a bulbous axon terminal in the S5 stratum (Fig. 5). In the 1 
retinas of vehicle-administered P23H rats, rod bipolar cells at P90 showed few 2 
cell bodies and a retraction of their dendrites (Fig. 5B, 5E). Dendritic branches 3 
were scarce, and some cells had virtually no dendrites whatsoever. The number 4 
of immunopositive cells appeared to decrease, and their cell bodies were not 5 
aligned in the orderly fashion found in wild-type rats (Fig. 5A, 5D). Moreover, a 6 
loss of complexity and inmunoreativity can be obseved in the axon terminals of 7 
these cells (Cuenca et al., 2004). By contrast, in P23H HU210-treated animals, 8 
bipolar cell dendrites were preserved (Fig. 5C, 5F; arrowheads), and the loss of 9 
cell bodies was not so extensive. Increased PKC-α imnunoreactivity and larger 10 
bulbous axon terminals, with lateral terminal varicosities, were found in central 11 
and peripheral retina of HU210-treated rats (Fig. 5C, 5F), as compared with 12 
untreated animals (Fig. 5B, 5E). Integrity of ON-rod bipolar cells was evaluated 13 
by measuring in the central retina of each experimental group the relative 14 
intensity of PKC-α immunoreactivity. As shown in Fig. 3D, ON-rod bipolar cells 15 
immunoreactivity in SD rats was significantly greater (Student’s t-test, p < 0.05) 16 
than that obtained in untreated P23H rats (58.3% with respect to SD), but not 17 
with respect to measured in HU210-treated animals (72.6% of the value in SD). 18 
 19 
3.5. HU210 preserves photoreceptor axon terminals and their synaptic contacts 20 
with bipolar cells 21 
Given that photoreceptor morphology was preserved in HU210-treated rats, 22 
we tested whether photoreceptor presynaptic terminals were protected by 23 
HU210 treatment. To this end, we performed staining for synaptophysin (SYP), 24 
a presynaptic-vesicle marker present throughout the axon terminals of cones 25 
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and rods (Fernandez-Sanchez et al., 2011). GNB3 antibody was used to stain 1 
ON-bipolar cells (Fernandez-Bueno et al., 2012). In 3-month-old untreated 2 
P23H rats, only an isolated immunoreactive punctate structure for SYP staining 3 
was found, indicating loss of photoreceptor axon terminals and giving the OPL 4 
the appearance of a discontinuous plexus (Fig. 6B, 6E; arrows). In the 5 
remaining cones of peripheral retina, mislocated SYP staining was found along 6 
the whole cell, from axon terminals to outer segments (Fig. 6E; arrowheads). By 7 
contrast, in HU210-treated P23H rats, a continuous strip of labeled 8 
photoreceptor terminals could be observed (Fig. 6C, 6F; arrows), indicating 9 
photoreceptor terminal preservation. Double staining for SYP and GNB3 10 
revealed synaptic contacts between rod spherules (labeled for SYP) and the 11 
dendritic tips of ON-bipolar cells (labeled for GNB3) in HU210-treated animals 12 
(Fig. 6C, 6F). In comparison, fewer of such contacts were observed in vehicle-13 
administered P23H rats (Fig. 6B, 6E). For quantification of these effects, we 14 
measured the relative area of SYP immunostaining in the OPL (surface of 15 
positive staining per mm of retinal section). As shown in Fig. 3E, photoreceptor 16 
axon terminals area in HU210-treated P23H rats was smaller (Student’s t-test, p 17 
< 0.01) than that measured in SD rats (35.1%), but significantly higher 18 
(Student’s t-test, p < 0.01) than that obtained in untreated P23H rats (18,1% 19 
with respect to SD). 20 
 21 
3.6. HU210 prevents loss of horizontal cell dendrites and their synaptic contacts 22 
with photoreceptors  23 
Horizontal cell bodies are located in the outermost INL of the retina and 24 
establish connections with both rod and cone photoreceptors. The only 25 
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horizontal cell subtype described in the rat retina can be identified using 1 
antibodies against calbindin. In wild-type rats, calbindin labeling reveals a 2 
punctate staining of dendritic arborization protruding from horizontal cell bodies 3 
and connecting with cone axon terminals, together with thin tangential axonal 4 
elongations in the OPL, ending in an extensive arborization connecting with 5 
rods (Fig. 7A, arrows). In 3-month-old P23H rats, a retraction and loss of 6 
horizontal cell dendritic tips was found (Fig. 7B; arrows), concomitantly with the 7 
decrease of stained photoreceptor rows. By contrast, in HU210-treated rat 8 
retinas, a higher number of horizontal cell bodies and terminals could be 9 
observed (Fig. 7C; arrows). 10 
To explore whether preservation of the dendritic arborization in horizontal 11 
cells correlated with preservation of synaptic connectivity in the OPL, we used 12 
antibodies against bassoon. Typical bassoon-immunoreactive spots were 13 
observed, with a horseshoe morphology corresponding to rod spherules (Fig. 14 
7D-7F; arrows). Double labeling with antibodies against bassoon and calbindin 15 
showed numerous pairings between photoreceptor axons and horizontal cell 16 
terminals in HU210-treated animals (Fig. 7I; arrows) as compared to fewer 17 
contacts observed in untreated P23H rats (Fig. 7H; arrows). These data indicate 18 
a preserving effect of HU210 on synaptic contacts between photoreceptors and 19 
horizontal cells. 20 
21 
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4. Discussion 1 
The present study demonstrates that systemic administration of the 2 
cannabinoid HU210 is capable of preserving retinal structure and function in 3 
homozygous P23H transgenic rats, a model of autosomal dominant RP. This is 4 
the first time that cannabinoid therapy has been assayed in RP. We have 5 
focused our study not only on photoreceptor morphology and function, but also 6 
on the secondary effects on photoreceptor connectivity and the structure of 7 
inner retinal cell layers. The slow retinal degeneration that takes place in P23H 8 
line 3 rats (Cuenca et al., 2004; Pinilla et al., 2005) makes this animal model 9 
closer to the human condition than other P23H lines and genetic mouse 10 
models, thus giving our results additional clinical relevance. 11 
In this study, we found that HU210 therapy in P23H rats ameliorated the 12 
loss of both rods and cones characteristic of these animals and preserved their 13 
morphology, as evidenced by specific immunostaining of both photoreceptor 14 
cell types. Their preservation was in concordance with the higher amplitudes, as 15 
well as the lower thresholds and latencies, of scotopic a- and b-waves found in 16 
HU210-treated as compared to untreated animals. In fact, the increases in the 17 
ONL thickness were significantly correlated with the maximum amplitudes of 18 
scotopic b-waves at P90. These results agree with those of our previous studies 19 
evaluating the neuroprotective effects of antioxidant and antiapoptotic agents in 20 
P23H rats (Fernandez-Sanchez et al., 2012a; Fernandez-Sanchez et al., 21 
2012b; Fernandez-Sanchez et al., 2011; Lax et al., 2011). In this study we have 22 
not included photopic ERGs, due to the low amplitude of the ERG responses at 23 
P90. 24 
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Previous studies have demonstrated that in the 23H rat model cones 1 
degenerate secondarily to rods (Garcia-Ayuso et al., 2013). Thus, 2 
morphological and functional state of cones depends of the survival of rods and, 3 
therefore, of the state of the degenerative process. In our results, regardless the 4 
neuroprotective effect of HU210 on retinal photoreceptors, P23H rats showed a 5 
significant loss of both rod and cones, as compared to wild-type animals. 6 
Accordingly, we can assume that the state of degeneration of these retinas was 7 
relatively advanced, as compared with shown in previous studies (Cuenca et 8 
al., 2004). Various mechanisms of cone-rod dependence for survival have been 9 
postulated: rods secrete an essential survival factor for cones (Leveillard et al., 10 
2004); rod loss causes oxidative damage to cones (Stone et al., 1999); retinal 11 
and choroidal degenerative changes impede normal photoreceptor nutrition 12 
(Marc and Jones, 2003; Marc et al., 2003); and degenerating rods generate a 13 
toxin that reaches cones by gap junctions, causing their death (Ripps, 2002). 14 
In addition to the preventive effects of HU210 on photoreceptor number, 15 
morphology and function, P23H HU210-treated rats experienced improved 16 
connectivity between photoreceptors and their postsynaptic neurons, i.e., 17 
horizontal and bipolar cells. Both presynaptic and postsynaptic elements, as 18 
well as synaptic contacts between photoreceptors and bipolar and horizontal 19 
cells, were preserved in HU210-treated P23H rats. Furthermore, in these rats, 20 
the number of both rod bipolar and horizontal cell bodies, as well as the density 21 
of their dendritic terminals, was higher than in vehicle-administered rats. These 22 
results strongly indicate that the effect of HU210 on retinal morphology and 23 
function is not cell specific and, therefore, extends not only to photoreceptors 24 
but also to other retinal cell types. Another interesting possibility is that the 25 
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preservation of the photoreceptor population prevents the occurrence of 1 
secondary degenerative changes in their postsynaptic neurons, thereby 2 
preventing the remodeling of the entire retinal circuitry (Jones and Marc, 2005; 3 
Marc et al., 2003). 4 
The neuroprotective effects of HU210 on retinal degeneration might be 5 
exerted through the endocannabinoid system. Endocannabinoids have been 6 
shown to provide neuroprotection against ischemia (Pellegrini-Giampietro et al., 7 
2009), traumatic brain injury (Shohami et al., 1993), inflammation-induced 8 
neuronal damage (Eljaschewitsch et al., 2006) and neurotoxicity (van der Stelt 9 
and Di Marzo, 2005). The proposed mechanisms for these actions include 10 
blockade of microglial activation (Ramirez et al., 2005), increase in neurotrophic 11 
factors (Khaspekov et al., 2004), reduction of calcium influx (Nadler et al., 1993) 12 
and antioxidant activity (El-Remessy et al., 2003), among others. Some of these 13 
mechanisms are mediated by the CB1 receptor (e.g. inhibition of glutamate 14 
release, decrease in cytosolic free Ca2+ concentration), whereas others 15 
implicate CB2 receptors, mainly through a series of glia-dependent anti-16 
inflammatory actions (Fernandez-Ruiz et al., 2007). HU210 has similar affinity 17 
for CB1 and CB2 receptors (Pertwee, 1999), whose immunoreactivity has been 18 
found in the retina of rodents and primates (Bouskila et al., 2012; Bouskila et 19 
al., 2013; Cecyre et al., 2013; Lopez et al., 2011; Straiker et al., 1999a; Yazulla, 20 
2008; Yazulla et al., 1999). Furthermore, evidence of cannabinoid function has 21 
been provided in ganglion cells (Lalonde et al., 2006; Middleton and Protti, 22 
2011), bipolar cells (Straiker et al., 1999b; Yazulla et al., 2000) and 23 
photoreceptors (Fan and Yazulla, 2003; Straiker and Sullivan, 2003). HU210 24 
has been shown to be 100 to 800 times more potent than THC (Ottani and 25 
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Giuliani, 2001), having a slightly longer duration of action than the analog 1 
natural cannabinoid (Little et al., 1989; Ottani and Giuliani, 2001). Furthermore, 2 
neuroprotective effects of HU210 have been demonstrated in Alzheimer’s 3 
disease (Ramirez et al., 2005), Parkinson’s disease (Walsh et al., 2010), 4 
ischemic damage (Leker et al., 2003) and neurotoxicity (Pope et al., 2010; 5 
Rubio et al., 2011), among others. 6 
Some of the neuroprotective mechanisms attributable to cannabinoids are 7 
independent of CB receptors. Previous reports have described the 8 
neuroprotective effects of cannabinoids via blocking ROS (Hampson et al., 9 
1998; Hampson et al., 2000). In this sense, it has been demonstrated that 10 
antioxidant receptor-independent cannabinoids provide neuroprotection in 11 
Parkinson’s disease (Garcia-Arencibia et al., 2007). HU210 has been found to 12 
be a potent lipophilic antioxidant, and it behaves as a protective agent against 13 
oxidative stress in neuronal cell lines (Marsicano et al., 2002). Moreover, 14 
antioxidant effects of HU210 have been evidenced in neural damage in diabetic 15 
mice (Dagon et al., 2007).  16 
From our results, we are not able to deduce the mechanisms involved in the 17 
neuroprotective actions of HU210 in the retina of P23H rats. Future studies 18 
using specific agonists for CB1 and CB2 receptors and antagonists for these 19 
receptors are necessary to determine if these effects are mediated by CB1 20 
and/or CB2 receptors and, in that case, what is/are the receptor(s) involved in 21 
these actions. These studies might also establish whether HU210-22 
neuroprotection result from a direct effect on photoreceptors or, instead, by an 23 
indirect effect through glia-dependent actions. Future studies are also needed 24 
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to establish the dose and schedule in which HU210 may exert its greatest 1 
neuroprotective effect. 2 
In RP disease, despite the use of therapies aimed at preventing cell death, 3 
the loss of photoreceptors in number and function usually leads to a dramatic 4 
remodeling of retinal circuits that would probably further compromise the 5 
transmission of visual information (Cuenca et al., 2004). In this context, the use 6 
of therapies such as cannabinoids, effective not only in preserving 7 
photoreceptor loss but also in slowing the degeneration of inner retinal layers, 8 
may be especially interesting in combination with other therapies based on the 9 
transplantation of stem cells, anti-inflammatory or anti-apoptotic agents, and 10 
artificial chips, among others. 11 
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Figure legends 1 
Fig. 1. ERG responsiveness in untreated and HU210-treated P23H rats. (A) 2 
Scotopic ERG traces in a untreated and HU210-treated P23H rat at P30, P60 3 
and P90. Units on the left of the panel indicate input flash intensities in log 4 
cd·s/m2. (B-D) Luminance-response curves in untreated (circle) and HU210-5 
treated (square) P23H rats at P30 (B), P60 (C) and P90 (D). Average 6 
amplitudes of a-waves were higher in treated animals (n=6) than in untreated 7 
P23H rats (n=5) at P60 and P90 (ANOVA, Bonferroni’s test, p < 0.001). b-8 
waves were also higher in treated rats, as compared to untreated rats, at P30, 9 
P60 and P90 (ANOVA, Bonferroni’s test, p < 0.001). *p < 0.05, **p < 0.001; 10 
ANOVA, Bonferroni’s test). 11 
Fig. 2. Assessment of the photoreceptor layer in untreated and HU210-treated 12 
P23H rats. Vertical sections and high magnification views from an untreated (A) 13 
and HU210-treated (B) P23H rat retina at P90. GNB3 antibody stains ON-14 
bipolar cells (red), whereas synaptophysin labels presynaptic vesicles in both 15 
OPL and IPL (green). Nuclei stained with TO-PRO (blue). Animals treated with 16 
HU210 display higher number of photoreceptor rows at the retinal ONL than 17 
untreated animals. ONL, outer nuclear layer. Scale bar: 1mm; inset: 50 µm. 18 
Fig. 3. Quantification of structural changes in untreated and HU210-treated 19 
P23H rats. (A) Average number of photoreceptor rows throughout the naso-20 
temporal axis in untreated (n = 5; circles) and HU210-treated (n = 5; squares) 21 
P23H rats at P90. The mean number of photoreceptor rows in HU210-treated 22 
P23H rats was 40% higher than observed in untreated rats (p < 0.001). (B) 23 
Average number of positively stained synaptic ribbons from nasal to temporal 24 
retina in untreated (n = 5; black bars) and HU210-treated (n = 5; white bars) 25 
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P23H rats. The mean number of Basson-immunoreactive spots was 25% higher 1 
in HU210-treated P23H rats, as compared to untreated animals (p < 0.01). (C) 2 
Average length of cones in the central retina of wild-type rats (Sprague Dawley, 3 
SD) (n = 5; grey bar) and P23H rats treated with vehicle (n = 5; black bar) or 4 
HU210 (n = 5; white bar). (D) Relative PKC-α immunoreactivity of ON-rod 5 
bipolar cells in the central retina of Sprague Dawley rats (SD) (n = 5; grey bar) 6 
and P23H rats treated with vehicle (n = 5; black bar) or HU210 (n = 5; white 7 
bar). (E) Relative area of SYP immunostaining of photoreceptor axon terminals 8 
in the OPL (surface of positive staining per mm of retinal section) of Sprague 9 
Dawley rats (SD) (n = 5; grey bar) and P23H rats treated with vehicle (n = 5; 10 
black bar) or HU210 (n = 5; white bar). *p < 0.05, **p < 0.001; Student’s t test. 11 
ON, optic nerve; OS, ora serrata.  12 
Fig. 4. Photoreceptor cell morphology in untreated and HU210-treated P23H 13 
rats. Vertical sections at P90 of retinas from wild-type rats (Sprague Dawley, 14 
SD) (A, D, G) and P23H rats treated with vehicle (B, E, H) or HU210 (C, F, I). 15 
(A-C) Recoverin-stained (cones and rods; red) and rhodopsin-stained (rod outer 16 
segments; green) retinas showing a more profuse degeneration in the vehicle-17 
treated P23H rat (B) than that observed in the HU210-treated P23H rat (C). 18 
Besides cones and rods, antibodies against recoverin specifically stained type 8 19 
(arrows) and type 2 (arrowheads) bipolar cells. (D-F) Cone staining for γ-20 
transducin shows smaller cell sizes, and shorter and swollen outer segments in 21 
vehicle-treated P23H rats (E) than in HU210-treated P23H rats (F). γ-transducin 22 
antibodies also stained some types of cone bipolar cells. Nuclei stained with a 23 
nuclear marker (blue). (G-I) High magnification of cone stainings, showing 24 
preservation in the HU210-treated P23H rat (I) of cone outer and inner 25 
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segments (arrows), and maintenance in this animal of axon and pedicle 1 
morphology (arrowheads). All images were collected from the central area of 2 
the retina, close to the optic nerve. OS, outer segment; IS, inner segment; ONL, 3 
outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, 4 
inner plexiform layer; GCL, ganglion cell layer; ONF, optic nerve fibers. Scale 5 
bar: 20µm. 6 
Fig. 5. ON-rod bipolar cells and their synaptic connectivity in untreated and 7 
HU210-treated P23H rats. PKC-α staining of ON-rod bipolar cells in vertical 8 
sections at P90 from wild-type rats (Sprague Dawley, SD) (A, D) and P23H rats 9 
treated with vehicle (B, E) or HU210 (C, F). Insets show higher magnification 10 
images of the bipolar cell dendritic arbors in the OPL. Nuclei stained with 11 
nuclear marker (blue). Note that cell bodies and dendrites (arrowheads) were 12 
more preserved in HU210-treated P23H rats than in untreated animals, in both 13 
central (B, C) and peripheral (E, F) retina. Scale bar: 20 µm and 10 µm (insets). 14 
Fig. 6. Photoreceptor presynaptic terminals in untreated and HU210-treated 15 
P23H rats. Vertical sections at P90 of retinas from wild-type rats (Sprague 16 
Dawley, SD) (A, D) and P23H rats treated with vehicle (B, E) or HU210 (C, F). 17 
GNB3 antibody stains ON-bipolar cells (red), whereas SYP labels presynaptic 18 
vesicles of cones and rods (green; arrows). Nuclei stained with nuclear marker 19 
(blue). Note that synaptic contacts between photoreceptors and bipolar cells are 20 
less deteriorated in HU210-treated P23H rats than in untreated animals, in both 21 
central (B, C) and peripheral (E, F) retina. Mislocated SYP staining was found in 22 
the soma of remaining cones in peripheral retina of P23H untreated animals (E; 23 
arrowheads). Scale bar: 20 µm. 24 
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Fig. 7. Horizontal cells and their synaptic contacts in untreated and HU210-1 
treated P23H rats. Vertical sections at P90 of retinas from wild-type rats 2 
(Sprague Dawley, SD) (A, D, G) and P23H rats treated with vehicle (B, E, H) or 3 
HU210 (C, F, I). Nuclei stained with nuclear marker (blue). (A-C) Horizontal 4 
cells labeled with antibodies against calbindin. Note that the number of 5 
horizontal cell terminals (arrows) in HU210-treated P23H rats was higher than in 6 
vehicle-treated animals. (D-F) Labeling of photoreceptor synaptic ribbons 7 
(arrows) with antibodies against bassoon. (G-I) Double immunolabeling for 8 
calbindin and bassoon showing a larger number of synaptic contacts (arrows) 9 
between photoreceptor and horizontal cells in HU210-treated rats (I) than 10 
observed in the untreated P23H rats (H). All images were collected from the 11 
central area of the retina, close to the optic nerve. Scale bar: 10 µm. 12 
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Table 1. Primary antibodies 
Molecular marker Antibody Source Working 
dilution 
Bassoon Mouse monoclonal (Cuenca et al., 2004) Stressgen 1:1000 
Calbindin D-28K Rabbit polyclonal (Cuenca et al., 2004) Swant 1:500 
GNB3 Rabbit polyclonal (Fernandez-Bueno et 
al., 2012) SIGMA 1:50 
PKC (α isoforms) Rabbit polyclonal (Cuenca et al., 2004) Santa Cruz Biotechnology 1:100 
Recoverin Mouse monoclonal (Cuenca et al., 2004) 
J.F. McGinnis, 
University of 
Oklahoma 
1:2000 
Rhodopsin Mouse monoclonal (Pinilla et al., 2007) Chemicon 1:200 
Synaptophysin Mouse, clone SY38 (Fernandez-Sanchez 
et al., 2011) Chemicon 1:500 
γ-Transducin Rabbit polyclonal (Cuenca et al., 2004) Cytosignal 1:200 
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Research highlights: 
 
> HU210 preserves retinal function.  
> HU210 preserves cone and rod structure. 
> HU210 preserves photoreceptor contacts with postsynaptic neurons. 
> Cannabinoids are potentially useful to delay retinal degeneration. 
